Pfizer’s Metsera hunger sees it beat Novo Nordisk’s obesity biopharma offer
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
List view / Grid view
The deal puts Pfizer’s plans to acquire the US firm, and a portfolio that includes injectable GLP-1 drugs, back on track.
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.